ClinicalTrials.Veeva

Menu
Houston Research Institute | Houston, TX logo

Houston Research Institute | Houston, TX

Research site
About
Houston Research Institute is dedicated to conducting clinical trials in the areas of Hepatology and Gastroenterology, with a special focus on fatty liver disease. We pride ourselves on conducting high quality research as a complement to the medical care that our volunteers receive from their routine care center.

Site insights

Top conditions

Top treatments

Resmetirom
MK-6024
TERN-501
HU6
Semaglutide
Lanifibranor
Survodutide
TERN-101
Cilofexor
Cagrilintide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Kira Harris

Verified by this site

Active trials

10 of 11 total trials

A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

The purpose of this study is to learn how well efinopegdutide works compared to placebo in people who have non-alcoholic steatohepatitis (NASH). Rese...

Active, not recruiting
Nonalcoholic Fatty Liver Disease
Fatty Liver, Nonalcoholic
Drug: Semaglutide
Drug: Placebo

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: IVA337

This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepat...

Enrolling
NASH
Cirrhosis, Liver
Drug: Resmetirom
Drug: Placebo

This is a randomized, blinded, placebo-controlled study of BOS-580 in obese participants at risk for, or with biopsy-confirmed, nonalcoholic steatohe...

Enrolling
Nonalcoholic Steatohepatitis (NASH)
Drug: Placebo
Drug: BOS-580

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling
Obesity
Drug: Placebo
Drug: survodutide

This study will evaluate the effect of efinopegdutide administration once every 2 weeks (Q2W) versus once weekly (Q1W) on mean relative reduction fro...

Active, not recruiting
Nonalcoholic Fatty Liver Disease
Metabolic Dysfunction-Associated Steatotic Liver Disease
Drug: Efinopegdutide

The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic live...

Enrolling
Alcohol-related Liver Disease
Drug: Cagrilintide
Drug: NNC0194-0499 placebo

This is a phase 2 randomized, double-blind, placebo-controlled parallel group study of 3 dose levels of HU6 in subjects with nonalcoholic steatohepat...

Active, not recruiting
Fatty Liver
Nonalcoholic Steatohepatitis
Drug: HU6
Other: Placebo

Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabe...

Active, not recruiting
Non-alcoholic Steatohepatitis
Drug: Placebo
Drug: Semaglutide

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firso...

Active, not recruiting
Nonalcoholic Steatohepatitis
Drug: Cilofexor (CILO)/Firsocostat (FIR)
Drug: PTM SEMA

Trial sponsors

Merck Sharp & Dohme (MSD) logo
Novo Nordisk logo
Boehringer Ingelheim logo
Boston Scientific logo
Gilead Sciences logo
I
Madrigal Pharmaceuticals logo
Rivus Pharmaceuticals logo
T

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems